Sanctuary Advisors LLC Has $480,000 Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Sanctuary Advisors LLC raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 26.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,057 shares of the company’s stock after buying an additional 5,505 shares during the quarter. Sanctuary Advisors LLC’s holdings in Hims & Hers Health were worth $480,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Renaissance Technologies LLC boosted its holdings in Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after purchasing an additional 3,205,108 shares during the period. Wellington Management Group LLP grew its position in Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after buying an additional 883,230 shares in the last quarter. Geode Capital Management LLC increased its stake in Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after acquiring an additional 482,177 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after acquiring an additional 328,142 shares in the last quarter. Finally, Carnegie Investment Counsel bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth approximately $5,531,000. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Price Performance

HIMS opened at $28.15 on Thursday. The stock has a market capitalization of $6.15 billion, a P/E ratio of 63.98 and a beta of 1.25. The company’s 50 day simple moving average is $26.15 and its 200-day simple moving average is $21.41. Hims & Hers Health, Inc. has a one year low of $8.09 and a one year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period last year, the company earned ($0.04) EPS. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44. Following the completion of the sale, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,399,273.20. This represents a 73.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Melissa Baird sold 58,750 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $19.57, for a total value of $1,149,737.50. Following the transaction, the chief operating officer now owns 630,166 shares of the company’s stock, valued at $12,332,348.62. The trade was a 8.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,111,616 shares of company stock worth $27,448,767 in the last quarter. 17.71% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. Piper Sandler restated a “neutral” rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. TD Cowen reiterated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Canaccord Genuity Group raised their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $22.80.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.